On Monday, International Paper Co (NYSE:IP)’s shares inclined 2.13% to $39.75.
International Paper (IP) will release third quarter 2015 earnings on Wednesday, October 28, 2015 before the opening of the New York Stock Exchange. The company will host a webcast to talk about earnings and current market conditions, starting at 9 a.m. ET (8 a.m. CT). All interested parties are invited to listen to the webcast via the company’s Internet site at http://www.internationalpaper.com by clicking on the Investors tab and going to the Webcasts and Presentations page.
International Paper Company operates as a paper and packaging company in North America, Europe, Latin America, Russia, Asia, Africa, and the Middle East. The company operates through three segments: Industrial Packaging, Printing Papers, and Consumer Packaging.
Matador Resources Co (NYSE:MTDR)’s shares gained 9.98% to $25.33.
Matador Resources Company (MTDR) an independent energy company engaged in the exploration, development, production and acquisition of oil and natural gas resources, with an emphasis on oil and natural gas shale and other unconventional plays and with a current focus on its Permian (Delaware) Basin operations in Southeast New Mexico and West Texas, recently closed the formerly declared sale of its wholly-owned partner that owns certain natural gas gathering and processing assets in the Delaware Basin in Loving County, Texas (the “Loving County System”), to a partner of EnLink Midstream Partners, LP (ENLK) (“EnLink”). The Loving County System comprises a cryogenic natural gas processing plant with about 35 million cubic feet per day of inlet capacity (the “Processing Plant”) and about six miles of high-pressure gathering pipeline which connects a Matador-owned gathering system to the Processing Plant.
Following the terms of the transaction, a partner of EnLink paid Matador consideration of about $143 million not taking into account customary purchase price adjustments. In conjunction with the sale of the Loving County System, Matador is dedicating its current leasehold interests in Loving County following a 15-year, fixed-fee gathering and processing agreement and providing a volume commitment in exchange for preceding one service. Matador can, at its option, dedicate any future leasehold acquisitions in Loving County to a partner of EnLink. In addition, Matador is retaining its natural gas gathering system up to a central delivery point and its other midstream assets in the area, counting oil and water gathering systems and salt water disposal wells.
Matador Resources Company, an independent energy company, engages in the exploration, development, production, and acquisition of oil and natural gas resources in the United States.
At the end of Monday’s trade, Plains All American Pipeline, L.P. (NYSE:PAA)‘s shares surged 0.15% to $33.76.
Plains All American Pipeline, L.P. (NYSE: PAA) and Plains GP Holdings (NYSE: PAGP) declared they will release third-quarter earnings after market close on Tuesday, November 3, 2015 and will hold the following joint webcast and conference call:
What: Third-quarter 2015 earnings webcast and conference call
When: Wednesday, November 4, 2015 11:00 a.m. ET; 10:00 a.m. CT
Plains All American Pipeline, L.P., through with its auxiliaries, engages in the transportation, storage, terminalling, and marketing of crude oil, natural gas liquids (NGL), natural gas, and refined products in the United States and Canada.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), ended its Monday’s trading session with -3.36% loss, and closed at $80.23.
Alnylam Pharmaceuticals, Inc. ( ALNY), a leading RNAi therapeutics company, and Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), declared that Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialization in territories outside of North America and Western Europe. This marks the first product from Alnylam’s Genetic Medicines pipeline to which Genzyme has opted in since the formation of the companies’ global alliance in January 2014, and the third product opt-in overall. Genzyme’s opt-in decision was based on encouraging clinical data from the Phase 1 trial of ALN-AT3, counting positive interim data that were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress in June 2015.
In January 2014, Alnylam and Genzyme formed an alliance to accelerate and expand the development and commercialization of RNAi therapeutics across the world. The alliance is structured as a multi-product geographic alliance in the field of rare diseases, i.e., programs in Alnylam’s Genetic Medicine Planned Therapeutic Area. Alnylam retains product rights in North America and Western Europe, while Genzyme obtained the right to access certain programs in Alnylam’s current and future Genetic Medicines pipeline in the rest of the world (ROW) through the end of 2019, together with certain broader co-development/co-commercialization rights and global rights for certain products. Alnylam maintains development and commercialization control for all programs in its territory.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
